Published in Mol Pharmacol on May 01, 2004
Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J (2005) 2.03
MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol (2009) 2.02
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int (2005) 1.83
Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J (2006) 1.23
Human ABCG2: structure, function, and its role in multidrug resistance. Int J Biochem Mol Biol (2011) 1.21
New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther (2007) 1.18
BCRP/ABCG2 in the placenta: expression, function and regulation. Pharm Res (2008) 1.17
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J (2014) 1.17
Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. Mol Cancer Ther (2009) 1.14
Quantum-SAR extension of the spectral-SAR algorithm: application to polyphenolic anticancer bioactivity. Int J Mol Sci (2009) 1.13
Disposition of flavonoids via enteric recycling: determination of the UDP-glucuronosyltransferase isoforms responsible for the metabolism of flavonoids in intact Caco-2 TC7 cells using siRNA. Mol Pharm (2007) 1.09
The challenge of exploiting ABCG2 in the clinic. Curr Pharm Biotechnol (2011) 1.06
Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J (2005) 1.04
Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats. AAPS J (2006) 1.04
Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J (2005) 1.03
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2). Br J Pharmacol (2007) 1.03
Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol (2011) 1.02
Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One (2011) 1.00
Secondary Metabolites from Plants Inhibiting ABC Transporters and Reversing Resistance of Cancer Cells and Microbes to Cytotoxic and Antimicrobial Agents. Front Microbiol (2012) 0.98
Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo). Pharm Res (2008) 0.96
Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2). AAPS J (2009) 0.92
Variable isoflavone content of red clover products affects intestinal disposition of biochanin A, formononetin, genistein, and daidzein. J Altern Complement Med (2008) 0.88
Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des (2014) 0.88
Preparation, in vitro and in vivo evaluation of polymeric nanoparticles based on hyaluronic acid-poly(butyl cyanoacrylate) and D-alpha-tocopheryl polyethylene glycol 1000 succinate for tumor-targeted delivery of morin hydrate. Int J Nanomedicine (2015) 0.87
A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLoS One (2009) 0.87
Absorption, Conjugation and Efflux of the Flavonoids, Kaempferol and Galangin, Using the Intestinal CACO-2/TC7 Cell Model. J Funct Foods (2009) 0.85
Oral epithelial stem cells - implications in normal development and cancer metastasis. Exp Cell Res (2014) 0.84
Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis. Drug Metab Dispos (2010) 0.84
Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter. J Pharmacol Exp Ther (2016) 0.82
Isoflavones, their Glycosides and Glycoconjugates. Synthesis and Biological Activity. Curr Org Chem (2017) 0.81
Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1. Br J Pharmacol (2009) 0.81
A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. AAPS J (2012) 0.80
A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells. Assay Drug Dev Technol (2013) 0.79
Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3). Int J Pharm (2009) 0.79
New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity. Drug Des Devel Ther (2013) 0.78
Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter. Curr Drug Metab (2015) 0.78
The in vitro cytotoxic activity of ethno-pharmacological important plants of Darjeeling district of West Bengal against different human cancer cell lines. BMC Complement Altern Med (2015) 0.77
Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways. RSC Adv (2012) 0.77
Chemopreventive Agents and Inhibitors of Cancer Hallmarks: May Citrus Offer New Perspectives? Nutrients (2016) 0.76
Phytochemistry and pharmacology of Ferula persica Boiss.: A review. Iran J Basic Med Sci (2017) 0.75
Optimization of subcritical water extraction parameters of antioxidant polyphenols from sea buckthorn (Hippophaë rhamnoides L.) seed residue. J Food Sci Technol (2013) 0.75
Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2. J Nat Prod (2011) 0.75
Novel 5-oxo-hexahydroquinoline derivatives: design, synthesis, in vitro P-glycoprotein-mediated multidrug resistance reversal profile and molecular dynamics simulation study. Drug Des Devel Ther (2017) 0.75
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro (2005) 2.60
MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol (2009) 2.02
Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther (2003) 1.35
Dietary organic isothiocyanates are cytotoxic in human breast cancer MCF-7 and mammary epithelial MCF-12A cell lines. Exp Biol Med (Maywood) (2004) 1.31
Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol (2005) 1.21
Pharmacokinetics of dietary phenethyl isothiocyanate in rats. Pharm Res (2005) 1.15
Determination of phenethyl isothiocyanate in human plasma and urine by ammonia derivatization and liquid chromatography-tandem mass spectrometry. Anal Biochem (2003) 1.13
Transport of gamma-hydroxybutyrate in rat kidney membrane vesicles: Role of monocarboxylate transporters. J Pharmacol Exp Ther (2006) 1.09
Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J (2012) 1.05
The role of monocarboxylate transporter 2 and 4 in the transport of gamma-hydroxybutyric acid in mammalian cells. Drug Metab Dispos (2007) 1.05
Monocarboxylate transporter (MCT) mediates the transport of gamma-hydroxybutyrate in human kidney HK-2 cells. Pharm Res (2007) 1.05
Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats. AAPS J (2006) 1.04
Effects of L-lactate and D-mannitol on gamma-hydroxybutyrate toxicokinetics and toxicodynamics in rats. Drug Metab Dispos (2008) 1.03
Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos (2006) 1.01
Concentration-effect relationships for the drug of abuse gamma-hydroxybutyric acid. J Pharmacol Exp Ther (2010) 1.01
Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. AAPS J (2009) 1.01
Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res (2004) 1.00
The drug of abuse gamma-hydroxybutyrate is a substrate for sodium-coupled monocarboxylate transporter (SMCT) 1 (SLC5A8): characterization of SMCT-mediated uptake and inhibition. Drug Metab Dispos (2009) 0.99
Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res (2003) 0.99
Pharmacokinetic interaction between the flavonoid luteolin and gamma-hydroxybutyrate in rats: potential involvement of monocarboxylate transporters. AAPS J (2008) 0.99
Mechanistic toxicokinetic model for gamma-hydroxybutyric acid: inhibition of active renal reabsorption as a potential therapeutic strategy. AAPS J (2010) 0.98
Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos (2005) 0.96
Characterization of monocarboxylate transport in human kidney HK-2 cells. Mol Pharm (2006) 0.94
Quercetin pharmacokinetics in humans. Biopharm Drug Dispos (2008) 0.94
Comparison of the effects of phenethyl isothiocyanate and sulforaphane on gene expression in breast cancer and normal mammary epithelial cells. Exp Biol Med (Maywood) (2009) 0.92
Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2). AAPS J (2009) 0.92
Monocarboxylate transporter-mediated transport of gamma-hydroxybutyric acid in human intestinal Caco-2 cells. Drug Metab Dispos (2009) 0.92
Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine. Pharm Res (2002) 0.90
New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors. Drug Metab Dispos (2004) 0.90
γ-Hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose. Mol Pharmacol (2012) 0.90
Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci (2003) 0.90
Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice. AAPS J (2012) 0.89
Effects of the flavonoid chrysin on nitrofurantoin pharmacokinetics in rats: potential involvement of ABCG2. Drug Metab Dispos (2006) 0.89
Pharmacokinetics and bioavailability of the bioflavonoid biochanin A: effects of quercetin and EGCG on biochanin A disposition in rats. Mol Pharm (2007) 0.89
Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J Pharm Sci (2004) 0.89
Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice. Drug Metab Dispos (2004) 0.88
Noninvasive real-time fluorescence imaging of the lymphatic uptake of BSA-IRDye 680 conjugate administered subcutaneously in mice. J Pharm Sci (2012) 0.88
Quantitative structure-activity relationship and quantitative structure-pharmacokinetics relationship of 1,4-dihydropyridines and pyridines as multidrug resistance modulators. Pharm Res (2005) 0.87
Choline uptake in human intestinal Caco-2 cells is carrier-mediated. J Nutr (2003) 0.87
Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab Dispos (2005) 0.86
Liquid chromatography-tandem mass spectroscopy assay for quercetin and conjugated quercetin metabolites in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.85
HPLC analysis of mitoxantrone in mouse plasma and tissues: application in a pharmacokinetic study. J Pharm Biomed Anal (2009) 0.84
Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence. Pharm Res (2012) 0.84
Chemopreventive and anti-angiogenic effects of dietary phenethyl isothiocyanate in an N-methyl nitrosourea-induced breast cancer animal model. Biopharm Drug Dispos (2012) 0.83
The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metab Dispos (2010) 0.83
Effects of flavonoids genistein and biochanin a on gene expression and their metabolism in human mammary cells. Nutr Cancer (2007) 0.83
Brain extracellular γ-hydroxybutyrate concentrations are decreased by L-lactate in rats: role in the treatment of overdoses. Pharm Res (2013) 0.83
Brain uptake of the drug of abuse γ-hydroxybutyric acid in rats. Drug Metab Dispos (2011) 0.83
5,7-Dimethoxyflavone and multiple flavonoids in combination alter the ABCG2-mediated tissue distribution of mitoxantrone in mice. Pharm Res (2011) 0.82
γ-Hydroxybutyrate blood/plasma partitioning: effect of physiologic pH on transport by monocarboxylate transporters. Drug Metab Dispos (2011) 0.82
Pharmacokinetics of alpha-naphthyl isothiocyanate in rats. J Pharm Sci (2005) 0.82
Formed and preformed metabolites: facts and comparisons. J Pharm Pharmacol (2008) 0.82
Membrane transport of dietary phenethyl isothiocyanate by ABCG2 (breast cancer resistance protein). Mol Pharm (2005) 0.81
Effects of monocarboxylate transporter inhibition on the oral toxicokinetics/toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone. J Pharmacol Exp Ther (2013) 0.81
In vivo modulation of 4E binding protein 1 (4E-BP1) phosphorylation by watercress: a pilot study. Br J Nutr (2010) 0.80
Dietary phenethyl isothiocyanate alters gene expression in human breast cancer cells. Evid Based Complement Alternat Med (2010) 0.80
A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. AAPS J (2012) 0.80
Biliary excretion in dogs: evidence for a molecular weight threshold. Eur J Pharm Sci (2010) 0.80
Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. Biochem Pharmacol (2005) 0.80
Interactions between the flavonoid biochanin A and P-glycoprotein substrates in rats: in vitro and in vivo. J Pharm Sci (2010) 0.80
Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S. J Pharm Sci (2011) 0.80
Effect of organic isothiocyanates on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res (2004) 0.80
Effects of single and multiple flavonoids on BCRP-mediated accumulation, cytotoxicity and transport of mitoxantrone in vitro. Pharm Res (2010) 0.79
Use of a local sensitivity analysis to inform study design based on a mechanistic toxicokinetic model for γ-hydroxybutyric acid. AAPS J (2011) 0.79
Mechanism-based pharmacodynamic modeling. Methods Mol Biol (2012) 0.79
Simultaneous determination of the flavonoids robinin and kaempferol in human breast cancer cells by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal (2010) 0.79
Effect of orally administered phenethyl isothiocyanate on hepatic gene expression in rats. Mol Nutr Food Res (2010) 0.78
Toxicokinetics/Toxicodynamics of γ-hydroxybutyrate-ethanol intoxication: evaluation of potential treatment strategies. J Pharmacol Exp Ther (2013) 0.78
Pharmacokinetics and bioavailability of the flavonoid 7,8-benzoflavone in rats. J Pharm Sci (2008) 0.78
ABC transporters and isothiocyanates: potential for pharmacokinetic diet-drug interactions. Biopharm Drug Dispos (2009) 0.78
Pharmacokinetics and biliary excretion of mitoxantrone in rats. J Pharm Sci (2010) 0.77
Mechanistic modeling of monocarboxylate transporter-mediated toxicokinetic/toxicodynamic interactions between γ-hydroxybutyrate and L-lactate. AAPS J (2014) 0.77
Effects of new 4-aryl-1,4-dihydropyridines and 4-arylpyridines on drug efflux mediated by multidrug resistance-associated protein 1. J Pharm Sci (2005) 0.77
Biochanin A inhibits breast cancer tumor growth in a murine xenograft model. Pharm Res (2008) 0.77
Mechanistic models describing active renal reabsorption and secretion: a simulation-based study. AAPS J (2012) 0.77
Determination of alpha-naphthylisothiocyanate and metabolites alpha-naphthylamine and alpha-naphthylisocyanate in rat plasma and urine by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.77
A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for γ-Hydroxybutyric Acid Overdose. Pharm Res (2014) 0.76
Effects of the isoflavonoid biochanin A on the transport of mitoxantrone in vitro and in vivo. Biopharm Drug Dispos (2010) 0.76
Real-time quantitative polymerase chain reaction for BCRP, MDR1, and MRP1 mRNA levels in lymphocytes and monocytes. Acta Haematol (2007) 0.76
The sulfated conjugate of biochanin A is a substrate of breast cancer resistant protein (ABCG2). Biopharm Drug Dispos (2011) 0.76
Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. AAPS J (2015) 0.76
Reevaluation of a quantitative structure pharmacokinetic model for biliary excretion in rats. Drug Metab Dispos (2012) 0.76
Effect of 3,4-methylenedioxymethamphetamine on the toxicokinetics and sedative effects of the drug of abuse, γ-hydroxybutyric acid. J Pharm Sci (2014) 0.75
Effects of the flavonoid biochanin A on gene expression in primary human hepatocytes and human intestinal cells. Mol Nutr Food Res (2007) 0.75
Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR. Biopharm Drug Dispos (2012) 0.75
Pharmacokinetics and bioavailability of a newly synthesized dihydropyridine compound with multidrug resistance reversal activity. Biopharm Drug Dispos (2005) 0.75
Interference of a sulfate conjugate in quantitative liquid chromatography/tandem mass spectrometry through in-source dissociation. Rapid Commun Mass Spectrom (2010) 0.75
A high-performance liquid chromatographic method for determination of the niguldipine analogue DHP-014. Biomed Chromatogr (2006) 0.75